Nasdaq · Healthcare
TANDEM DIABETES CARE INC (TNDM)
As-reported financials and recent SEC filings for TANDEM DIABETES CARE INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.01B
Net income
$-204.7M
Net margin
-20.2%
Diluted EPS
$-3.04
ROE
-131.9%
P/E (TTM)
—
Market cap
$1.11B
Debt / equity
2.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.01B | $940.2M | $747.7M | $801.2M | $702.8M |
| Gross profit | $546.0M | $489.6M | $367.7M | $413.0M | $376.2M |
| Operating income | $-187.3M | $-99.1M | $-233.2M | $-92.8M | $22.7M |
| Net income | $-204.7M | $-96.0M | $-222.6M | $-94.6M | $15.6M |
| Diluted EPS | $-3.04 | $-1.47 | $-3.43 | $-1.47 | $0.24 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-17
View on EDGAR →42026-06-04
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →Go deeper on TNDM
Search TANDEM DIABETES CARE INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.